Rukobia (fostemsavir) / ViiV Healthcare, BMS  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rukobia (fostemsavir) / ViiV Healthcare
NCT01384734 / 2011-000437-36: HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

Completed
2b
254
US, Europe, RoW
BMS-663068 400 mg, BMS-663068 800 mg, BMS-663068 600 mg, BMS-663068 1200 mg, Raltegravir 400 mg, Tenofovir 300 mg, Ritonavir 100 mg, Atazanavir 300 mg
ViiV Healthcare, ViiV Healthcare UK (No. 4) Limited, Bristol-Myers Squibb International Corporation
Infection, Human Immunodeficiency Virus
02/13
05/17
NCT01009814: Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1

Completed
2
50
Europe
BMS-663068, Ritonavir
ViiV Healthcare, GlaxoSmithKline
HIV Infections
06/10
06/10
2011-000437-36: This clinical research study will access the effectiveness (how well it works), safety, tolerability (how well the body stands the drug) and blood levels of combined doses of BMS-663068/GSK3684934, Raltegravir and Tenofovir.

Completed
2
250
Europe
Atazanavir, BMS-663068-03/GSK3684934, BMS-663068-03, BMS-232632, J05AE03, Film-coated tablet, Capsule, hard, Reyataz, Norvir
ViiV Healthcare UK Limited, Bristol-Myers Squibb International Corporation, ViiV Healthcare UK (No. 4) Limited, Bristol-Myers Squibb International Corporation
Human immunodeficiency virus type 1 (HIV-1)-infection, HIV infection, Diseases [C] - Virus Diseases [C02]
 
 
2020-001029-30: Use of Fostemsavir in HIV-1 infected children and adolescents with Multi Drug-Resistant virus Uso de fostemsavir en niños y adolescentes infectados por el VIH-1 con virus multirresistente

Ongoing
1/2
60
Europe
Fostemsavir, BMS-663068-03/GSK3684934A, not applicable, Tablet
Fondazione Penta ONLUS, ViiV Healthcare
HIV-1 infection in children and adolescents with Multi Drug-Resistant virus Infección por VIH-1 en niños y adolescentes con virus multirresistente, HIV-1 infection in children and adolescents who are failing their current combination antiretroviral therapy and have dual- or triple-class antiretroviral resistance Infección por VIH-1 en niños y adolescentes que están fracasando con su terapia antirretroviral combinada actual y tienen resistencia a los antirretrovirales de clase doble o triple., Diseases [C] - Virus Diseases [C02]
 
 
NCT04648280: Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance

Recruiting
1/2
60
Europe, US, RoW
Fostemsavir
PENTA Foundation, ViiV Healthcare, PHPT Foundation, Hospital Universitario 12 de Octubre, Cromsource
HIV Infections With Multi Drug Resistant Virus
06/25
06/28

Download Options